Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase I study is to determine the highest dose of carboplatin and
gemcitabine (gemcitabine hydrochloride) that can be given safely to subjects with gynecologic
cancer, in combination with stereotactic body radiation therapy (SBRT). This dose is called
the maximum tolerated dose (MTD). To determine the MTD, patients will receive different
amounts of carboplatin and gemcitabine.